• Mean Percent Change From Baseline in Brief Pain Inventory Score (BPI) of Average Pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
• Mean Percent Change From Baseline in Brief Pain Inventory Score (BPI) of Average Pain [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

• Evaluate the long-term efficacy of Kadian NT during a 12-month period by assessing pain intensity (PI)
• in the past 24 hours using the Brief Pain Inventory (BPI) Short Form, and the Global Assessment of Study Drug
• Evaluate opioid withdrawal symptoms in subjects who receive Kadian NT upon completion of 12-months exposure
• or early termination from the study using the Clinical Opiate Withdrawal Scale (COWS)
• Evaluate plasma naltrexone, 6-B-naltrexol, and morphine concentrations at Visits 2 through 15 in selected male
• and female subjects for pharmacokinetic study.

Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.

Inclusion Criteria:

• Subject 18-70 years of age
• Subject agrees to refrain from taking any opioid medications other than study medication during study period.
• History of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline

Exclusion Criteria:

• Subject has a documented history of allergic reaction or clinically significant intolerance to morphine or other opioids, such that treatment with morphine is contraindicated.
• Subject is pregnant or breast-feeding.
• Subject is receiving chemotherapy, or has an active malignancy of any type or has been diagnosed with cancer within the past three years (excluding squamous or basal cell carcinoma of the skin).
• Subject has a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit.
• Subject has a Body Mass Index (BMI)>45kg/m2.